Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders.


Journal

Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157

Informations de publication

Date de publication:
2023
Historique:
received: 07 12 2021
revised: 08 03 2022
accepted: 17 03 2022
pubmed: 10 5 2022
medline: 11 3 2023
entrez: 9 5 2022
Statut: ppublish

Résumé

Hyperandrogenic skin disorders, such as hirsutism, acne and alopecia, affect approximately 10-20% of women of reproductive age, reducing quality of life and causing psychological impairment. Spironolactone is a commonly used antiandrogen, especially in women who are not sexually active or have contraindications to hormonal contraceptives. The aim of this study was to evaluate the effects of spironolactone, especially after its withdrawal, in patients with hyperandrogenic skin disorders. Retrospective analysis of 63 women with hyperandrogenic skin symptoms due to polycystic ovary syndrome (PCOS), treated with spironolactone for at least 6 months as first-line treatment. After a mean time of treatment of 25.7 months, all patients reported a significant improvement in hyperandrogenic skin disorders; only 5 patients were dissatisfied and required the addition of an oral contraceptive. The therapy was well tolerated and the most frequent side-effect was intermestrual bleeding in 68.2% of cases, affecting mainly classic PCOS phenotype. Thirthyeight patients showed prolonged effects 33.7 months after spironolactone withdrawal, whereas 20 relapsed 17.5 months after discontinuation. No significant difference in clinical and biochemical parameters was observed between these two groups both at baseline and after spironolactone treatment. Ovulatory PCOS patients were treated for a shorter time and reported earlier relapse than classic PCOS patients. Spironolactone is an effective and safe treatment for hyperandrogenic skin disorders, showing long-lasting effects even several months after its discontinuation.

Identifiants

pubmed: 35532249
pii: EMIDDT-EPUB-123191
doi: 10.2174/1871530322666220509051746
doi:

Substances chimiques

Spironolactone 27O7W4T232

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

188-195

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Chiara Sabbadin (C)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Francesca Beggiao (F)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Carlotta Keiko Vedolin (C)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Gloria Orlando (G)

Department of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy.

Eugenio Ragazzi (E)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Filippo Ceccato (F)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Mattia Barbot (M)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Luciana Bordin (L)

Department of Molecular Medicine-Biological Chemistry, University of Padova, Padova, Italy.

Gabriella Donà (G)

Department of Molecular Medicine-Biological Chemistry, University of Padova, Padova, Italy.

Alessandra Andrisani (A)

Department of Women's and Children's Health, University of Padova, Padova, Italy.

Anna Belloni Fortina (A)

Department of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy.

Carla Scaroni (C)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Decio Armanini (D)

Department of Medicine, Endocrinology Unit, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH